Portal de Periódicos da CAPES

An Overview of Two Human Trials of Perfluorocarbon Emulsions in Noncardiac Surgery

2017; Lippincott Williams & Wilkins; Volume: 52; Issue: 1S Linguagem: Inglês

10.1097/shk.0000000000000986

1540-0514

Donat R. Spahn, Peter E. Keipert,

Trauma, Hemostasis, Coagulopathy, Resuscitation

∗Institute of Anesthesiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland †KEIPERT Corp. Life Sciences Consulting, San Diego, California Address reprint requests to Donat R. Spahn, MD, FRCA, Institute of Anesthesiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland. E-mail: [email protected] Conflict of interest statement (past 5 years): Donat R. Spahn: Dr. Spahn's academic department is/has been receiving grant support from the Swiss National Science Foundation, Berne, Switzerland; the Ministry of Health (Gesundheitsdirektion) of the Canton of Zurich, Switzerland, for Highly Specialized Medicine; the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland; the Swiss Foundation for Anesthesia Research, Zurich, Switzerland; Bundesprogramm Chancengleichheit, Berne, Switzerland; CSL Behring, Berne, Switzerland; Vifor SA, Villars-sur-Glâne, Switzerland. Dr. Spahn is the cochair of the ABC-Trauma Faculty, managed by Physicians World Europe, Mannheim, Germany, and sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland; CSL Behring GmbH, Marburg, Germany; and LFB Biomédicaments, Courtaboeuf Cedex, France. In the past 5 years, Dr. Spahn has received honoraria or travel support for consulting or lecturing from Danube University of Krems, Austria; US Department of Defense, Washington, USA; Abbott AG, Baar, Switzerland; AMGEN GmbH, Munich, Germany; AstraZeneca AG, Zug, Switzerland; Baxter AG, Volketswil, Switzerland; Baxter S.p.A., Roma, Italy; Bayer, Zürich, Switzerland and Berlin, Germany; B. Braun Melsungen AG, Melsungen, Germany; Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland; CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland; Curacyte AG, Munich, Germany; Daiichi Sankyo (Schweiz) AG, Thalwil, Switzerland; Ethicon Biosurgery, Sommerville, New Jersey, USA; Fresenius SE, Bad Homburg v.d.H., Germany; Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland); GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany; Haemonetics, Braintree, MA, USA; Janssen-Cilag, Baar, Switzerland and Beerse, Belgium; LFB Biomédicaments, Courtaboeuf Cedex, France; Merck Sharp & Dohme AG, Luzern, Switzerland; Novo Nordisk A/S, Bagsvärd, Denmark; Octapharma AG, Lachen, Switzerland, Organon AG, Pfäffikon/SZ, Switzerland; PAION Deutschland GmbH, Aachen, Germany; Pharmacosmos A/S, Holbaek, Denmark; Photonics Healthcare B.V., Utrecht, The Netherlands; ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria; Roche, Reinach, Switzerland; Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany; Schering-Plough International, Inc., Kenilworth, New Jersey, USA; Tem International GmbH, Munich, Germany; Verum Diagnostica GmbH, Munich, Germany; Vifor Pharma, Munich, Germany, Vienna, Austria and St. Gallen, Switzerland. Conflict of interest statement (past 5 years): Peter E. Keipert: During the conduct of the clinical studies with perflubron emulsion described in this paper, Dr. Keipert was employed by Alliance Pharmaceutical as the Program Director responsible for overseeing the preclinical and clinical development of perflubron emulsion, until Alliance had to terminate operations in 2002. Over the past 5 years, Dr. Keipert has worked as an independent consultant in this field as founder and President of KEIPERT Corp. Life Sciences Consulting (San Diego, CA). In this capacity, Dr. Keipert has received consulting fees from CymBlood, Ltd, at the University of Essex (Colchester, UK), and from Prolong Pharmaceuticals (South Plains, NJ) for work to support their Hb-based oxygen carrier (HBOC) development. From 2004 to 2013, Dr. Keipert was also employed by Sangart Inc. (San Diego, CA), as Vice President, Clinical Development, for the development of MP4, a pegylated hemoglobin solution for use as an oxygen therapeutic. Since 2016, Dr. Keipert has been employed by PAREXEL International, a clinical services organization, where his work does not involve any conflict of interest with the development of Hb or PFC-based oxygen therapeutic agents.